Medeor Therapeutics

company

About

Medeor Therapeutics is a biotechnology company that dedicates to dedicates to the development of personalized cellular immunotherapies.

  • South San Francisco,California,United States
  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$57M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Medeor Therapeutics, Inc.

Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$75.80M
Medeor Therapeutics has raised a total of $75.80M in funding over 2 rounds. Their latest funding was raised on Jan 22, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 22, 2018 Grant $18.80M 1 California Institute for Regenerative Medicine Detail
Nov 27, 2017 Series B $57M 5 RA Capital Management Detail

Investors

Number of Lead Investors
Number of Investors
2
6
Medeor Therapeutics is funded by 6 investors. California Institute for Regenerative Medicine and RA Capital Management are the most recent investors.
Investor Name Lead Investor Funding Round
California Institute for Regenerative Medicine Yes Grant
RA Capital Management Yes Series B
6 Dimensions Capital Series B
Sofinnova Investments Series B
Vivo Capital Series B
WuXi Healthcare Ventures Series B

Employee Profiles

Number of Employee Profiles
6
Medeor Therapeutics has 6 current employee profiles, including Executive Giovanni Ferrara
Executive
Board member
Advisor
Advisor
Advisor